Tammaro Chiara, Guida Michela, Appetecchia Federico, Biava Mariangela, Consalvi Sara, Poce Giovanna
Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro, 5, 00185 Rome, Italy.
Pharmaceuticals (Basel). 2023 Jan 29;16(2):203. doi: 10.3390/ph16020203.
Enterovirus B (EV-B)-related diseases, which can be life threatening in high-risk populations, have been recognized as a serious health problem, but their clinical treatment is largely supportive, and no selective antivirals are available on the market. As their clinical relevance has become more serious, efforts in the field of anti-EV-B inhibitors have greatly increased and many potential antivirals with very high selectivity indexes and promising in vitro activities have been discovered. The scope of this review encompasses recent advances in the discovery of new compounds with anti-viral activity against EV-B, as well as further progress in repurposing drugs to treat these infections. Current progress and future perspectives in drug discovery against EV-Bs are briefly discussed and existing gaps are spotlighted.
肠道病毒B（EV-B）相关疾病在高危人群中可能危及生命，已被公认为严重的健康问题，但目前其临床治疗主要是支持性的，市场上尚无选择性抗病毒药物。随着其临床相关性变得更加严重，抗EV-B抑制剂领域的研究工作大幅增加，已发现许多具有非常高选择性指数和良好体外活性的潜在抗病毒药物。本综述涵盖了具有抗EV-B病毒活性的新化合物发现方面的最新进展，以及药物重新利用以治疗这些感染的进一步进展。简要讨论了抗EV-B药物发现的当前进展和未来前景，并突出了现有差距。
